FluoroPharma Medical

FluoroPharma Medical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of FluoroPharma Medical (FPMI) as of Oct 24, 2026 is 43.00 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 84.83 % — a change of -49.31% (lower).

FCF Conversion

43.00 %

YoY

-49.31%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of FluoroPharma Medical is 2016 43.00 % . FCF Conversion Rate (FCF/EBITDA) of FluoroPharma Medical was 2015 84.83 % . It decreases by -49.31% lower compared to the previous year.

The FluoroPharma Medical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
78,387.38 USD
Jan 1, 2015
84.83 USD
Jan 1, 2016
43.00 USD
The FluoroPharma Medical FCF Conversion history
YEARFCF ConversionYoY
43.00 %-49.31%
84.83 %-99.89%
78,387.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

FluoroPharma Medical Stock analysis

What does FluoroPharma Medical do? FluoroPharma Medical Inc is an innovative company from the USA that specializes in molecular imaging. It was founded in 2003 and is based in Boston, Massachusetts. The company's goal is to improve the diagnosis and treatment of cardiovascular and cancer diseases. The business model of FluoroPharma Medical is based on the development of radioactive tracers that are used in conjunction with imaging techniques such as PET (Positron Emission Tomography). These tracers are typically administered in the form of radiopharmaceuticals and allow real-time tracking of metabolic processes in the body of patients. The information obtained is used by doctors to make diagnoses and optimize treatment. FluoroPharma Medical specializes in the development of tracers specifically for cardiovascular and cancer diseases. These include the tracer BFPET (up to 3 hours), which is used for the diagnosis of coronary heart disease, and the tracer CardioPET (up to 3 hours), which is used for the diagnosis of cardiovascular diseases. In addition, the company is working on other tracers that are intended for the diagnosis of various types of cancer, such as prostate cancer, breast cancer, and lung cancer. FluoroPharma Medical is divided into different divisions to better organize its activities. The Research and Development division is responsible for the development of new tracers and conducting clinical studies. The Production division is responsible for the manufacturing and distribution of radiopharmaceuticals. Marketing and distribution are handled by the Sales and Marketing division, which works closely with doctors and hospitals. The products of FluoroPharma Medical are currently still in the development phase and not commercially available. However, the company is working closely with various universities and medical facilities to test its tracers in clinical trials. The aim is to demonstrate the effectiveness and safety of the tracers and obtain approval from the FDA (Food and Drug Administration). FluoroPharma Medical has established itself as a pioneer in the field of molecular imaging and is committed to further improving the diagnosis and treatment of cardiovascular and cancer diseases. With its innovative tracers and focus on clinical practice, the company has the potential to significantly improve the medical care of patients in the future. FluoroPharma Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FluoroPharma Medical stock

FCF Conversion Rate (FCF/EBITDA) of FluoroPharma Medical is 43.00 % in 2016.

FCF Conversion Rate (FCF/EBITDA) of FluoroPharma Medical changed from 84.83 % to 43.00 %, representing a -49.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) FluoroPharma Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s FluoroPharma Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — FluoroPharma Medical

All Key Metrics — FluoroPharma Medical